DBV Technologies SA Sponsored ADR

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DBV Technologies to Participate in Upcoming AAAAI 2021 Congress

DBV Technologies Announces Appointment of Michele F. Robertson as Chief Legal Officer

DBV Technologies to Participate in SVB Leerink Global Partners Healthcare Conference

Monthly information regarding the total number of voting rights and

Monthly information regarding the total number of voting rights and total number of shares of the Company as of January 31, 2021

After hitting a major regulatory roadblock, DBV Technologies sees a path to approval for its leading candidate.

Why DBV Technologies Stock Popped Today

DBV Technologies (DBVT) stock is soaring higher on Friday after providing an update on its upcoming peanut allergy treatment. The post DBVT Stock: DBV Technologies Soars on Big Peanut Allergy Patch News appeared first on InvestorPlace.

DBVT Stock: DBV Technologies Soars on Big Peanut Allergy Patch News

DBV Technologies Provides Update on Investigational Viaskin™ Peanut for Children Ages 4-11 Years

DBV Technologies Announces Change in U.S. Reporting Status and Final Approval of Global Restructuring Process

Monthly information regarding the total number of voting rights and total number of shares of the Company as of December 31, 2020

Monthly information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2020

DBV Technologies Announces Leadership Changes

Monthly information regarding the total number of voting rights and 

Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2020

Montrouge, France, November 10, 2020 DBV Technologies to Highlight Data on Viaskin ™ Peanut Treatment Delivery and Patient Experience at ACAAI 2020

DBV Technologies to Highlight Data on Viaskin™ Peanut Treatment Delivery and Patient Experience at ACAAI 2020

DBV Technologies S.A. (NASDAQ: DBVT) shares absolutely exploded on Monday after the firm announced that the Marketing Authorization Application (MAA) for its peanut allergy treatment was validated by the European Medicines Agency (EMA).

Is This Peanut Allergy Treatment Back on the Table?

DBV Technologies Announces Filing and Validation of Marketing Authorization Application for Viaskin™ Peanut by European Medicines Agency 

DBV Technologies Reports September 30, 2020 Cash Position

Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2020

Monthly information regarding the total number of voting rights and  total number of shares of the Company as of August 31, 2020

DBV Technologies to Participate in Multiple September Investor Conferences

Monthly information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2020

Shares of DBV Technologies  tumbled 8.5% in premarket trading on Wednesday, the day after the company said it had received a complete response letter from the Food and Drug Administration for its experimental peanut allergy treatment.

DBV discloses FDA concerns about experimental peanut allergy treatment

ATLANTA--(BUSINESS WIRE)--Holzer & Holzer, LLC is investigating whether DBV Technologies S.A. (“DBV Technologies” or the “Company”) (NASDAQ: DBVT) complied with federal securities laws.

SHAREHOLDER ALERT: Investigation of DBV Technologies Announced by Holzer & Holzer, LLC

The FDA rejected the company’s application for its peanut-allergy patch.

Why DBV Technologies Stock Is Plunging Today

DBV Technologies Receives Complete Response Letter from FDA for Viaskin Peanut BLA in Children Ages 4-11 Years

DBV Technologies Reports First Half 2020 Financial Results

News for DBV Technologies SA Sponsored ADR Stock (DBVT)